Brief: Expres2ion Signs Option To License Agreement With Adaptvac Regarding Unique Breast Cancer Vaccine
26/02/2020 07:40
Feb 26 (Reuters) - ExpreS2ion Biotech Holding AB
EXPRS2.ST :
* EXPRES2ION SIGNS OPTION TO LICENSE AGREEMENT WITH ADAPTVAC
REGARDING UNIQUE BREAST CANCER VACCINE
* EXPRES2ION BIOTECH HOLDING AB - OPTION PRICE ENTAILS NO
UPFRONT
FEE AND CAN MAXIMUM AMOUNT TO DKK 1.2M (SEK 1.7M) DURING FULL
OPTION TERM.
* EXPRES2ION BIOTECH HOLDING AB - TERMS OF AGREEMENT WILL
CONTAIN
FINANCIAL CONSIDERATION TO ADAPTVAC IN FORM OF UPFRONT PAYMENT
AT SIGNATURE OF DKK 2.5M
Source text for Eikon: ID:nWkrbhHj1y
Further company coverage: EXPRS2.ST
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on ExpreS2ion Biotech Holding AB
See all newsBrief: Expres2ion Biotech To Raise SEK 19.3 Million From Warrants And Share Issue
Brief: ExpreS2ion Reports Q2 Loss Of SEK 9.7 Million
Brief: Expres2ion Biotech Says DSMB Recommends Expanding 450 Μg Cohort
Brief: Expres2ion Biotech Holding Q1 2026 Operating Income SEK 6.87 Mln
Brief: Expres2ion Updates ES2B-C001 Phase I Programme and Reports Additional Preliminary Immunogenicity and Safety Observations